These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25409334)

  • 1. Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.
    Lu HK; Gray LR; Wightman F; Ellenberg P; Khoury G; Cheng WJ; Mota TM; Wesselingh S; Gorry PR; Cameron PU; Churchill MJ; Lewin SR
    PLoS One; 2014; 9(11):e113341. PubMed ID: 25409334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.
    Wightman F; Lu HK; Solomon AE; Saleh S; Harman AN; Cunningham AL; Gray L; Churchill M; Cameron PU; Dear AE; Lewin SR
    AIDS; 2013 Nov; 27(18):2853-62. PubMed ID: 24189584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
    Rasmussen TA; Schmeltz Søgaard O; Brinkmann C; Wightman F; Lewin SR; Melchjorsen J; Dinarello C; Østergaard L; Tolstrup M
    Hum Vaccin Immunother; 2013 May; 9(5):993-1001. PubMed ID: 23370291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir.
    Ling L; Kim M; Soper A; Kovarova M; Spagnuolo RA; Begum N; Kirchherr J; Archin N; Battaglia D; Cleveland D; Wahl A; Margolis DM; Browne EP; Garcia JV
    mBio; 2024 Sep; 15(9):e0163224. PubMed ID: 39136440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies.
    Gray LR; Cowley D; Welsh C; Lu HK; Brew BJ; Lewin SR; Wesselingh SL; Gorry PR; Churchill MJ
    Mol Psychiatry; 2016 Apr; 21(4):574-84. PubMed ID: 26303660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
    Williams SA; Chen LF; Kwon H; Ruiz-Jarabo CM; Verdin E; Greene WC
    EMBO J; 2006 Jan; 25(1):139-49. PubMed ID: 16319923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G.
    Jeeninga RE; Hoogenkamp M; Armand-Ugon M; de Baar M; Verhoef K; Berkhout B
    J Virol; 2000 Apr; 74(8):3740-51. PubMed ID: 10729149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitors Panobinostat and Romidepsin enhance
    Schnell AP; Kohrt S; Aristodemou A; Taylor GP; Bangham CRM; Thoma-Kress AK
    Front Immunol; 2022; 13():978800. PubMed ID: 36052071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
    Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
    J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB.
    Ying H; Zhang Y; Zhou X; Qu X; Wang P; Liu S; Lu D; Zhu H
    PLoS One; 2012; 7(11):e48832. PubMed ID: 23166597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1.
    Campbell GR; Bruckman RS; Chu YL; Spector SA
    J Biol Chem; 2015 Feb; 290(8):5028-5040. PubMed ID: 25540204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.